Company: HQL
Filing Date: 2025-12-08
Form Type: N-CSR
Source: 0001104659-25-119341
Chunk: 77

Company: abrdn Life Sciences Investors
Filing Date: 2025-12-08
Form: N-CSR
Chunk 77
---
.C. 78c(a)(58)(A)). |

As of the fiscal year ended September 30, 2025, the Audit Committee members were: Jeffrey Bailey Rose DiMartino Kathleen Goetz C. William Maher Todd Reit

| (b) | Not applicable. |

Item 6. Schedule of Investments. (a) Included as part of the Report to Shareholders filed under Item 1 of this Form N-CSR. (b) Not applicable. Item 7. Financial Statements and Financial Highlights for Open-End Management Investment Companies. Not applicable. Item 8. Changes in and Disagreements with Accountants for Open-End Management Investment Companies. Not applicable. Item 9. Proxy Disclosures for Open-End Management Investment Companies. Not applicable. Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies. Not applicable. Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract. The statement regarding the basis for approval of the investment advisory contract is included in the response to Item 1, above. Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies. Pursuant to the Registrant's Proxy Voting Policy and Procedures, the Registrant has delegated responsibility for its proxy voting to its Adviser, provided that the Registrant's Board of Trustees has the opportunity to periodically review the Adviser's proxy voting policies and material amendments thereto. The proxy voting policies of the Registrant are included herewith as Exhibit (d) and policies of the Adviser are included as Exhibit (e). Item 13. Portfolio Managers of Closed-End Management Investment Companies. (a)(1) PORTFOLIO MANAGER BIOGRAPHIES As of the date of filing this report, Jason Akus, M.D./M.B.A., Ashton L. Wilson, Christopher Abbott, Robert Benson, Kelly Girskis, Ph.D., Richard Goss, and Loretta Tse, Ph.D. are members of a team that analyzes investments on behalf of the Fund. Dr. Akus exercises ultimate decision-making authority with respect to investments.

| Individual & Position          | Past Business Experience                                                                                                                                                                                                                                                                                                                                    | Served on the Fund Since |
| Jason Akus, M.D./M.B.A         
 Head of Healthcare Investments | Head of Healthcare Investments of the investment adviser and is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas. He joined the predecessor investment adviser in 2001